Daejeon, South Korea

Cheol-Won Park



Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Location History:

  • Taejon, KR (2004)
  • Daejeon, KR (2009)

Company Filing History:


Years Active: 2004-2009

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Cheol-Won Park

Introduction

Cheol-Won Park is a notable inventor based in Daejeon, South Korea, recognized for his significant contributions to the field of pharmaceutical sciences. With a portfolio of two patents, Park has demonstrated a robust commitment to innovation, particularly in the development of therapeutic agents aimed at improving health outcomes.

Latest Patents

Cheol-Won Park's latest patents include groundbreaking inventions that address critical medical challenges. The first patent pertains to "Caspase inhibitors containing isoxazoline ring," which provides an isoxazoline derivative as a potent inhibitor against various caspases. This invention is pivotal for its role in developing therapeutic compositions that can prevent inflammation and apoptosis. The second patent, "Orally available peptidic thrombin inhibitors," introduces novel thrombin inhibitors effective as anticoagulants. These peptide derivatives exhibit high antithrombotic activity and enhanced oral bioavailability, representing a significant advancement in anticoagulant therapies.

Career Highlights

Cheol-Won Park is currently associated with LG Life Sciences Limited, a prominent company in the field of life sciences and pharmaceuticals. In his role, Park continues to contribute to innovative projects that leverage his expertise in drug design and development, thereby influencing the medical landscape positively.

Collaborations

Throughout his career, Cheol-Won Park has teamed up with distinguished coworkers such as Hye-Kyung Chang and Yeong-Soo Oh. These collaborations have fostered an environment of creativity and innovation, enabling the development of advanced therapeutic solutions that benefit the healthcare sector.

Conclusion

In conclusion, Cheol-Won Park's inventive work has substantial implications for the pharmaceutical industry. His developments in caspase inhibitors and thrombin inhibitors continue to push the boundaries of therapeutic innovation, ultimately striving to enhance patient care and health. With ongoing contributions and collaborations, Park remains a key figure in advancing medical research and innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…